Cortexyme to Present at the Canaccord Genuity Growth Conference on August 7th
31 Julho 2019 - 5:05PM
Business Wire
-- Presentation to be webcast on Cortexyme’s
website
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage
biopharmaceutical company pioneering a novel disease-modifying
therapeutic approach to treat a key underlying cause of Alzheimer’s
and other degenerative diseases, today announced Casey Lynch, the
company’s chief executive officer, chairman, and co-founder, will
present at the Canaccord Genuity Growth Conference on Wednesday,
August 7th, 2019 at 9:00 a.m. EDT (6:00 a.m. PDT) in Boston.
A live webcast of the presentation can be accessed at the
Investor Calendar page under the News & Events heading of the
Cortexyme investor site (ir.cortexyme.com). The webcast will be
archived at that location for 90 days.
About Cortexyme, Inc.
Cortexyme (Nasdaq: CRTX) is a clinical stage biopharmaceutical
company pioneering a novel disease-modifying therapeutic approach
to treat a key underlying cause of Alzheimer’s disease and other
degenerative diseases. Cortexyme is targeting a specific,
infectious pathogen found in the brain of Alzheimer’s patients and
tied to neurodegeneration and neuroinflammation in animal models.
The company’s lead investigational medicine, COR388, is the subject
of the GAIN trial, an ongoing Phase 2/3 clinical study in patients
with mild to moderate Alzheimer’s disease. More information about
the trial can be found at www.GAINtrial.com. To learn more about
Cortexyme, visit www.cortexyme.com.
Forward-Looking Statements
Statements in this press release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“expect,” “believe,” “will,” “may,” “should,” “estimate,”
“project,” “outlook,” “forecast” or other similar words.
Forward-looking statements are based on Cortexyme’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. Factors that could cause
actual results to differ include, but are not limited to, the risks
and uncertainties described in the section titled “Risk Factors” in
the final prospectus related to Cortexyme’s initial public offering
filed with the Securities and Exchange Commission on May 9, 2019
and Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on June 12, 2019. Forward-looking statements
contained in this press release are made as of this date, and
Cortexyme undertakes no duty to update such information except as
required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190731005689/en/
Hal Mackins For Cortexyme, Inc. hal@torchcomllc.com (415)
994-0040
Quince Therapeutics (NASDAQ:QNCX)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Quince Therapeutics (NASDAQ:QNCX)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024